Skip to main content

Table 1 Patient- and tumor characteristics

From: Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial

Patients completed all study parts n = 42
Age years (mean, range) 63 (35–89)
Tumor size mm (mean, range) 21 (6–33)
Positive nodal status 17 (41%)
Tumor grade (NHG)  
 I 9 (21%)
 II 17 (41%)
 III 16 (38%)
Mitotic index  
 1 23 (55%)
 2 5 (12%)
 3 14 (33%)
ER (n = 30)  
 Positive 27 (90%)
 Negative 3 (10%)
PR (n = 30)  
 Positive 24(80%)
 Negative 6 (20%)
HER2 (n = 29)  
 0 7 (24%)
 1+ 10 (34%)
 2+ 7 (24%)
 3+ 5 (17%)
Ki67 index (n = 26)  
 Low 15 (58%)
 High 11 (42%)
HMGCR (n = 38)  
 Positive 24 (63%)
 Negative 14 (37%)
  1. NHG Nottingham histologic grade I-III (post-treatment pathological report), Mitotic index according to Nottingham criteria (post-treatment pathological report).
  2. Baseline tumor data (pre-treatment): ER (estrogen receptor), PR (progesterone receptor), HER2 (human epidermal growth factor receptor 2), Ki67 high if >20%, HMGCR positive if any cytoplasmic staining.